obesity
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
August 22, 2025Medical Communications, Research and Development Hepatology, Novo Nordisk, US Food and Drug Administration, clinical trial, hepatitis, obesity
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as a treatment for adults with …
Lilly reports positive results from trial of obesity candidate
August 8, 2025Medical Communications, Research and Development Eli Lilly and Company, Obesity, cardiovascular risk, high blood pressure, obesity
Eli Lilly and Company (Lilly) has announced topline results from its phase 3 ATTAIN-1 trial, showing that orforglipron – a …
MetP Pharma releases positive data on intranasal semaglutide administration
July 22, 2025Research and Development Diabetes, MetP Pharma, Neurology, Obesity, central nervous system, diabetes, obesity, peptides, semaglutide
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering neuroactive peptides, particularly semaglutide, directly …
Ciloa secures €6.5m from French government to advance obesity and T2 diabetes therapy
July 9, 2025Research and Development Ciloa, Diabetes, France 2030, Obesity, adiponectin, funding, obesity, type 2 diabetes
French biotech company, Ciloa, has received €6.5m in funding through France 2030 to advance its lead candidate, APN-sEV, targeting obesity …
Pila Pharma raises SEK 20m to advance new oral obesity treatment
July 8, 2025Research and Development Novo Nordisk, Obesity, Ozempic, Pila Pharma, Wegovy, obesity, semaglutide, type 2 diabetes
Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital increase to advance the development …
Novo Nordisk’s therapy delivers significant weight loss in trial
June 25, 2025Research and Development Novo Nordisk, Obesity, obesity, weight loss, weight-related medical conditions
Novo Nordisk has announced promising results from its phase 3 REDEFINE 1 trial, showing that investigational weight loss therapy, CagriSema, …
Novo Nordisk unveils new semaglutide data on obesity and heart disease at ECO 2025
May 12, 2025Research and Development Cardiology, Novo Nordisk, Obesity, Ozempic, cardiometabolic conditions, heart disease, obesity, semaglutide
Danish biopharma, Novo Nordisk, has announced that it will present new data on metabolic and cardiovascular health at the upcoming …
Pfizer selects once-daily obesity drug for advancement
July 12, 2024Research and Development Obesity, Pfizer Inc, clinical trials, obesity
Pfizer has announced the selection of its preferred once-daily modified release formulation for danuglipron, with a plan to conduct dose …
Biophytis gains IND approval from FDA for obesity study
July 11, 2024Medical Communications Biophytis, IND, Obesity, clinical trial, obesity
Biophytis has announced that it has received investigational new drug (IND) approval from the US Food and Drug Administration (FDA) …
Eli Lilly launches digital healthcare process
January 5, 2024Medical Communications Diabetes, Eli Lilly, Obesity, diabetes, obesity
Eli Lilly has announced its new digital healthcare experience, LillyDirect, which will benefit patients in the US with obesity, migraine …
Teva Pharmaceuticals shares phase 3 data for Ajovy as migraine treatment
December 6, 2023Research and Development Neurology, Teva Pharmaceuticals, ajovy, obesity
Teva Pharmaceuticals has announced data from a post hoc analysis of two phase 3 clinical studies around the effectiveness of …
Novo Nordisk acquires Embark Biotech and its lead metabolic programme
August 31, 2023Business Services Cardiology, Novo Nordisk, Obesity, acquisition, metabolics, obesity
Novo Nordisk has officially acquired the biopharmaceutical company Embark Biotech, along with its lead asset metabolic programme. The teams will …
UK plans £40m drug trial for Novo Nordisk’s Wegovy to aid NHS in treating obesity
June 7, 2023Research and Development NHS, Novo Nordisk, Obesity, Wegovy, clinical trial, obesity
The UK Government has announced plans to launch a pilot programme which will provide GPs with Novo Nordisk’s Wegovy (semaglutide), …
Novo Nordisk to expand obesity study into oral treatment
April 22, 2021Novo Nordisk, obesity
Novo Nordisk is planning to initiate a Phase IIIa study of oral semaglutide in obesity, expanding on its Phase IIIa …
Novo Nordisk obesity treatment successful in clinical trials
March 24, 2021Research and Development Novo Nordisk, obesity
New results from Novo Nordisk’s Phase III study on obesity saw clinically relevant weight loss, without weight regain, in people …
